


Study looks at co-use of CYP2D6-metabolizing opioids, antidepressants in seniors

July 23 2024, by Elana Gotkine



For older nursing home (NH) residents, use of CYP2D6-metabolized opioids concomitantly with CYP2D6-inhibiting antidepressants is associated with worsening pain and increased risk of opioid-related adverse events (ORAEs), according to a [study published](#) online July 23

in the *Annals of Internal Medicine*.

Yu-Jung Jenny Wei, Ph.D., from the College of Pharmacy at The Ohio State University in Columbus, and colleagues examined the associations of concomitant use of CYP2D6-metabolized opioids and [antidepressants](#) with [clinical outcomes](#) and ORAEs in a retrospective cohort study using a target trial emulation framework.

Data were included for 29,435 long-term residents aged 65 years and older receiving CYP2D6-metabolized opioids with a disease indication for antidepressant use who initiated CYP2D6-inhibiting versus CYP2D6-neutral antidepressants.

The researchers found that use of CYP2D6-metabolized opioids concomitantly with CYP2D6-inhibiting antidepressants was associated with increased adjusted rate ratio of worsening pain compared with CYP2D6-neutral antidepressants (1.13).

In addition, CYP2D6-inhibiting antidepressants were associated with higher adjusted incidence rate ratios of pain-related hospitalization, [pain](#)-related emergency department visits, and opioid use disorder (1.37, 1.49, and 1.93, respectively); no differences were seen in physical function, depression, and [opioid overdose](#).

"When co-use of CYP2D6-metabolizing opioids and antidepressants is clinically needed, selecting CYP2D6-neutral antidepressants, rather than CYP2D6-inhibiting antidepressants, may provide better or equal clinical and adverse outcomes," the authors write.

More information: Yu-Jung Jenny Wei et al, Clinical and Adverse Outcomes Associated With Concomitant Use of CYP2D6-Metabolized Opioids With Antidepressants in Older Nursing Home Residents, *Annals of Internal Medicine* (2024). [DOI: 10.7326/M23-3109](https://doi.org/10.7326/M23-3109)

Copyright © 2024 [HealthDay](#). All rights reserved.

Citation: Study looks at co-use of CYP2D6-metabolizing opioids, antidepressants in seniors (2024, July 23) retrieved 23 July 2024 from <https://medicalxpress.com/news/2024-07-cyp2d6-metabolizing-opioids-antidepressants-seniors.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.